Wingspan Announces its eTMF for Official Electronic Trial Master File has Been Selected by Europe's Largest Biopharmaceutical Company
Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file.
Wingspan announces that Actelion Pharmaceuticals, a top 20 biopharmaceutical company, has selected Wingspan eTMF as its official electronic trial master file. The company, based in Switzerland, outlined specific goals of the trial master file implementation including providing key management metrics, increasing inspection readiness, saving time, reducing costs and increasing eTMF quality. Wingspan eTMF allows Actelion access to comprehensive metrics and reports in real time and integrates with the company’s existing applications. Because Wingspan eTMF is cloud-based, Actelion’s clinical trial specialists will have 24-hour access to trial related documents managed by Wingspan eTMF and easy external access from any location for all users, including CROs and partners.
Additionally, Actelion selected Wingspan given the technology company’s specialized focus on eTMF and strong client references from Pfizer and ICON, plc.
Wingspan Principal and CEO, Troy Deck said, "We are thrilled to have Actelion as a client and extraordinarily excited to be able to support their worldwide research through the use of our eTMF platform. Wingspan’s technical excellence and focus on trial efficiency aligns well with Actelion’s core values of Innovation and Results-Driven approach. Working together, we will continue to shape and improve the TMF landscape through refinement and expansion of our powerful and distinct capabilities."
After signing contractual agreements last week, Wingspan project managers joined the Actelion team in Switzerland to kick-off the implementation project. Wingspan will work with Actelion to launch its pilot project in mid-February with a larger rollout in June.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
